Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease

Striatal dopamine D2 receptor binding was studied in vivo with positron emission tomography in seven patients with early Parkinson's disease using [11C]–raclopride. The patients had unilateral symptoms and none of them had received levodopa treatment. The accumulation of [11C]–raclopride in the striatum was rapid and reached a steady state at approximately 40 min after injection. The binding of [11C]–raclopride was measured in the striatum and cerebellum: The total striatal radioactivity in both hemispheres was counted and the respective striatum/cerebellum ratios were calculated. The striatum/cerebellum ratio of [11C]–raclopride binding was significantly (p < 0.01) increased in the hemisphere contralateral to the parkinsonian symptoms as compared with the opposite hemisphere. Thus, this study demonstrates that there is denervation supersensitivity in dopamine D2 receptor binding in early Parkinson's disease.

[1]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[2]  G. Sedvall,et al.  Raclopride, a new selective ligand for the dopamine-D2 receptors , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  Y. Agid,et al.  D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.

[4]  K. L. Leenders,et al.  Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.

[5]  H Lundqvist,et al.  Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease , 1988, Acta neurologica Scandinavica.

[6]  M. Raichle,et al.  MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans , 1987, Neurology.

[7]  J. Korf,et al.  Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET) , 1987, Journal of the Neurological Sciences.

[8]  G. Antoni,et al.  Synthesis of L- and D-[methyl-11C]methionine. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  P. Hartvig,et al.  Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.

[10]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[11]  L. Auer,et al.  Effect of Serotonin and its Antagonist Ketanserin on Pial Vessels , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  A. Lang,et al.  Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.

[13]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[14]  C. Nahmias,et al.  Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[16]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[17]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.